Targeting hidden tumor vulnerabilities through synthetic lethality, metabolic and epigenetic dependencies, and precision oncology approaches designed to overcome tumor growth and drug resistance.
Advancing precision oncology therapies and rational combinations designed to target the core vulnerabilities and drivers of molecularly defined cancers.
Focused on patients with limited treatment options, our trials use precision medicine and predictive biomarkers to accelerate the development of targeted therapies.